Gamna-Gandy bodies (siderotic nodules) are small (1-10 mm) focal lesions characterized by hemosiderin and calcium deposition within the splenic parenchyma. They form through organization of focal hemorrhage foci in splenic sinusoids in the setting of portal hypertension. Congestion and increased sinusoidal pressure cause small focal hemorrhage foci that organize over time with fibrous tissue, hemosiderin (iron), and calcium deposition. They are a classic finding of cirrhosis and portal hypertension. Clinically asymptomatic and discovered incidentally on MRI. On MRI — particularly gradient-echo (GRE) T2* and SWI (susceptibility-weighted imaging) sequences — they appear as multiple millimetric hypointense foci with prominent 'blooming' artifact. They are typically invisible on CT and rarely recognized as hyperechoic foci on US.
Age Range
30-80
Peak Age
55
Gender
Male predominant
Prevalence
Uncommon
Portal hypertension increases pressure in the splenic vein and sinusoids. Under increased sinusoidal pressure, thin-walled sinusoidal vessels undergo focal microhemorrhages — small erythrocyte extravasations occur. These focal hemorrhage foci organize over time: erythrocyte destruction leads to hemoglobin release, and hemoglobin degradation produces hemosiderin (iron-protein complex) deposition. Concurrently, inflammatory response in the focal hemorrhage area generates fibrosis and dystrophic calcification develops. The result is that each focus transforms into an organized granuloma-like structure composed of hemosiderin + calcium + fibrous tissue. Hemosiderin is a strong paramagnetic substance (Fe³⁺ ion) that dramatically shortens T2/T2* relaxation — this is why Gamna-Gandy bodies show prominent signal loss (blooming artifact) on MRI, particularly on GRE and SWI sequences. Calcium deposition also contributes to the susceptibility effect but hemosiderin's effect is dominant. These lesions are typically too small (<5 mm) to be visible on CT and calcium concentration alone does not significantly increase CT density; however, MR susceptibility sequences can detect even millimetric hemosiderin deposits.
Widespread multiple millimetric markedly hypointense foci with blooming artifact in splenic parenchyma on GRE T2* or SWI sequences — pathognomonic MR finding of Gamna-Gandy bodies in the setting of portal hypertension. This finding is not seen this extensively and prominently in any other splenic pathology.
On GRE T2* and SWI sequences, widespread multiple millimetric (1-10 mm) markedly hypointense foci are seen throughout the splenic parenchyma. These foci may be invisible or barely detectable on spin-echo T2 — GRE/SWI sequences are far more sensitive for hemosiderin detection. On SWI, blooming artifact causes the foci to appear 2-3 times larger than their actual size. The foci show homogeneous distribution throughout the splenic parenchyma without preference for any particular segment or region. Their number can range from tens to hundreds.
Report Sentence
Widespread multiple millimetric hypointense foci with prominent blooming artifact in the splenic parenchyma on GRE T2*/SWI sequences, consistent with Gamna-Gandy bodies (siderotic nodules) in the setting of portal hypertension.
On T1-weighted sequences, Gamna-Gandy bodies may appear as small hypointense foci but sensitivity is low. Many foci are invisible on T1 because hemosiderin does not affect T1 contrast as dramatically as T2/T2*. They do not enhance after gadolinium — the organized fibrous+hemosiderin+calcium structure is avascular.
Report Sentence
Small hypointense foci are observed in the splenic parenchyma on T1-weighted sequences; no post-gadolinium enhancement is seen.
On non-contrast CT, Gamna-Gandy bodies are mostly invisible because their size is small (1-5 mm) and density difference falls below CT spatial resolution. Rarely, larger bodies with dense calcification may be visible as faint hyperdense foci. Accompanying splenomegaly, cirrhosis findings (nodular liver contour, ascites) and portal hypertension findings (varices, collaterals) support the diagnosis.
Report Sentence
No specific CT findings for Gamna-Gandy bodies are observed; accompanying splenomegaly and portal hypertension findings are present; correlation with MR GRE/SWI is recommended.
In the portal venous phase, the spleen is usually enlarged (>13 cm). Portal hypertension signs are observed: splenomegaly, splenic vein dilatation (>10 mm), gastric/esophageal varices, splenorenal shunt, recanalized umbilical vein, ascites. The liver may show nodular contour (cirrhosis). These findings establish the clinical context for Gamna-Gandy bodies.
Report Sentence
Splenomegaly and portal hypertension findings (varices, collaterals, ascites) are observed; MR GRE/SWI evaluation is recommended for Gamna-Gandy bodies in the setting of cirrhosis.
On B-mode US, Gamna-Gandy bodies are mostly invisible. Rarely, they may be recognized as multiple small (1-3 mm) hyperechoic foci in the splenic parenchyma — calcium and hemosiderin deposition increases echo reflectivity. These foci do not produce posterior acoustic shadow (size too small). Accompanying splenomegaly and portal hypertension findings (ascites, varices) support the diagnosis.
Report Sentence
Multiple small hyperechoic foci are observed in the splenic parenchyma on B-mode US; Gamna-Gandy bodies are likely in the setting of portal hypertension; MR GRE/SWI confirmation is recommended.
On DWI, Gamna-Gandy bodies may appear as signal loss foci due to the susceptibility artifact sensitivity of EPI-based sequences. However, DWI is not the primary diagnostic sequence — GRE T2*/SWI has far superior sensitivity. Localized signal artifacts may also be seen on ADC maps.
Report Sentence
Signal loss foci due to susceptibility artifact are observed in the splenic parenchyma on DWI, which may be consistent with Gamna-Gandy bodies; correlation with GRE T2*/SWI is recommended.
Criteria
Develops in the setting of cirrhosis and portal hypertension. Splenomegaly, varices, and ascites accompany.
Distinct Features
Most common cause. Nodular liver contour and portal hypertension findings are prominent. Gamna-Gandy bodies serve as an additional radiologic sign confirming cirrhosis.
Criteria
Develops in chronic hemolytic anemias (sickle cell disease, thalassemia, spherocytosis). Iron deposition from hemolysis accelerates Gamna-Gandy formation.
Distinct Features
Portal hypertension findings may be absent. Hemolysis-driven iron deposition is dominant. Diffuse hemosiderin deposition in spleen and liver manifests as T2 signal loss. In sickle cell disease, autosplenectomy from autoinfarction may have developed.
Criteria
Develops in non-cirrhotic portal hypertension causes (portal vein thrombosis, Budd-Chiari). Portal vein thrombosis leads to congestive splenomegaly.
Distinct Features
Liver may not show nodular contour. Thrombus or cavernous transformation of the portal vein is seen. Spleen is congestively enlarged and Gamna-Gandy bodies are proportional to the degree of portal hypertension.
Distinguishing Feature
Sarcoidosis nodules are hypodense on CT, T2 hypointense on MRI but do not show blooming as prominently as Gamna-Gandy on GRE/SWI. Hilar lymphadenopathy and pulmonary involvement accompany sarcoidosis; portal hypertension findings are absent.
Distinguishing Feature
Calcified granulomas are visible as hyperdense dots on CT (unlike Gamna-Gandy which is typically invisible on CT). On MRI, calcified granulomas may also be T2 hypointense but are generally larger (3-10 mm) and fewer in number. TB/histoplasmosis history is differentiating.
Distinguishing Feature
Hemangioma shows high T2 signal as a focal mass — completely different from the prominent T2/GRE signal loss of Gamna-Gandy bodies. Hemangioma enhances; Gamna-Gandy does not.
Distinguishing Feature
Lymphoma nodules are larger (>1 cm), hypodense on CT with mild diffusion restriction on MRI. Gamna-Gandy bodies are millimetric, invisible on CT with prominent blooming on GRE/SWI. B symptoms accompany lymphoma.
Urgency
routineManagement
surveillanceBiopsy
Not NeededFollow-up
no-follow-upGamna-Gandy bodies are clinically benign and require no specific treatment. They serve as a radiologic marker of portal hypertension and support cirrhosis diagnosis. The lesions themselves are asymptomatic. Clinical management is directed at the underlying portal hypertension/cirrhosis. No follow-up is needed for the lesions themselves but they are monitored within the cirrhosis and portal hypertension surveillance framework.
Gamma-Gandy bodies are a splenic manifestation of portal hypertension and require no treatment. Their presence supports the diagnosis of portal hypertension. Clinical importance lies in not confusing them with other pathologies.